Xtl Biopharmaceuticals (XTLB) Gross Profit (2011 - 2024)

Xtl Biopharmaceuticals (XTLB) posted quarterly Gross Profit of -$43000.0 for Q4 2024, down 125.9% on a QoQ basis from $166000.0 in Q3 2014.

Xtl Biopharmaceuticals (XTLB) Gross Profit (2011 - 2024) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Gross Profit for 5 consecutive years, with -$43000.0 the latest figure, recorded in Q4 2024.

Quarterly Gross Profit changed N/A year-over-year to -$43000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $820000.0 (changed N/A YoY) and the FY2024 annual result came in at $3000.0, changed N/A from the prior year.
Gross Profit eased to -$43000.0 in Q4 2024 per XTLB's latest filing, from $166000.0 in the prior quarter.
Over the last five years, Gross Profit for XTLB reached as high as -$43000.0 in Q4 2024 and fell as low as -$43000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Xtl Biopharmaceuticals	2.60 Bn	2.60 Bn	-

Download Data